-
2023-04-06
Ensifentrine Completes Dosing of First Patient in ENHANCE - CHINA Phase III Trial for COPD
Nuance Pharma announces dosing of first patient in the ENHANCE - China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease ("COPD") of its novel
-
2023-03-14
Bentrio™鼻喷剂 活力上线 亮相中国香港!
优锐医药亚太区域首款商业产品,Bentrio™鼻喷剂已在中国香港首发上市!
-
2023-03-03
Clinical Study Demonstrates Bentrio's Superior Nasal Residence Time and Rheological Properties
Altamira Therapeutics Ltd. reported that data from a recent peer-reviewed clinical study involving Bentrio nasal spray's residence time and other rheological properties demonstrated superiority vs. a saline control
-
2023-02-14
Altamira Therapeutics to Report Bentrio Clinical Data, in House Dust Mite and Grass Pollen Allergic Rhinitis, at Feb. 25 AAAAI Annual Meeting
Altamira Therapeutics Ltd. announced that data from three clinical studies with the Company's Bentrio nasal spray in allergic rhinitis will be presented February 25, at the Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI)
-
2023-01-24
Altamira Therapeutics Provides Update on Clinical Trials with Bentrio
Altamira Therapeutics Ltd. today provided an update on the clinical trials with Bentrio® in seasonal allergic rhinitis (SAR)
-
2022-12-20
Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD
Verona Pharma (Nasdaq: VRNA) announces positive results of its Phase 3 ENHANCE-1 trial evaluating nebulized ensifentrine for the maintenance treatment of COPD
-
2022-11-28
Partnership with DKSH to launch Bentrio™ Nasal Spray in Hong Kong and Macau
Nuance Pharma announces partnership with DKSH Hong Kong (DKSH HK) Business Unit Healthcare to launch BentrioTM nasal spray in Hong Kong and Macau, marking the very first milestone of Nuance
-
2022-11-04
优锐医药首席运营官陈晨 对话蔻德 - 新浪《蕊智会》
优锐医药首席运营官陈晨博士受邀参与由新浪健康主办的《蕊智会》- 蔻德联合高端访谈,深度探讨中国罕见病领域的发展历程、解决路径与前景展望。